Pancreatic cancer remains one of oncology's most intractable challenges, with most patients experiencing rapid disease progression after standard chemotherapy. Against this backdrop, any signal of durable disease control in a molecularly defined subgroup carries meaningful clinical weight — particularly as precision oncology strategies for pancreatic cancer lag far behind those for breast or ovarian malignancies.
The NIRA-PANC trial enrolled 37 patients with metastatic or unresectable pancreatic cancer harboring DNA damage repair gene alterations, administering the PARP inhibitor niraparib at weight- and platelet count-adjusted doses across 28-day cycles. Among 29 efficacy-evaluable patients, the six-month progression-free survival rate reached 41.4%, with a median PFS of 4.4 months and a median overall survival of 10.3 months. The BRCA1/2 germline-positive subgroup (n=14) performed best, achieving a six-month PFS rate of 50% and median OS of 12.1 months — outcomes that compare favorably to historical benchmarks for second-line pancreatic cancer. Non-BRCA DDR-altered patients showed a six-month PFS of 33% and median OS of 10.3 months, suggesting residual signal even beyond canonical BRCA mutations. Anemia was the most frequent adverse event, occurring in roughly one-quarter of patients, with no treatment-related fatalities.
PARP inhibitors have established efficacy in BRCA-mutated breast and ovarian cancers, but evidence in pancreatic cancer has been more fragile. The POLO trial previously demonstrated olaparib's PFS benefit as maintenance therapy in germline BRCA-mutated pancreatic cancer, though without a clear overall survival advantage. NIRA-PANC extends the therapeutic hypothesis to somatic DDR alterations beyond BRCA, a broader — and genomically heterogeneous — population. The critical caveats are substantial: only 29 patients were evaluable, confidence intervals around the primary endpoint are extraordinarily wide (4.7%–100%), and the single-arm design precludes causal attribution of outcomes to niraparib. Enrollment criteria and prior treatment history also introduce selection bias. At this stage, NIRA-PANC is best read as hypothesis-generating — reinforcing the biological rationale for PARP inhibition in DDR-deficient pancreatic cancer while underscoring the urgent need for randomized, biomarker-stratified trials in this space.